Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

When cancer research turns to the immune system – the critical role of peptides and immunopeptidomics

In this interview, AZoM speaks to Rohan Thakur, the President of Life Science Mass Spectrometry at Bruker, about what the opportunities of the market are and how Bruker is planning on rising to the challenge.

From Bruker Daltonics 22 Feb 2023

Ketamine appears to hold promise in treating cocaine-use disorders

As cocaine use continues to climb across the United States, scientists have struggled to develop an effective pharmacological approach to treat the devastating disorder.

20 Feb 2023

Utilizing CRISPR to discover new therapy options for COPD

In this interview, we speak to Ceri Wiggins, a Director at AstraZeneca, about the many applications of CRISPR and its role in discovering new COPD therapies.

From Society for Laboratory Automation and Screening (SLAS) 20 Feb 2023

Scientists discover how a "poisoned" form of protein could spur cancer formation

Scientists at Scripps Research, with collaborators in Japan, have discovered how a "poisoned" form of a protein could set off a cascade of events that encourage the growth of some cancers.

17 Feb 2023

Beckman Coulter Life Sciences presenting at SLAS2023

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will have a full team of dedicated professionals and informative programming at the upcoming Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition.

From Beckman Coulter Life Sciences 16 Feb 2023

Pharma companies could provide new, affordable drugs by refocusing their spending, experts say

High drug prices are not justified by industry's spending on research and development (R&D), argue experts in The BMJ today.

16 Feb 2023

Repurposing or improving drugs for spinocerebellar ataxia type 5

A team of researchers has developed a new method to screen FDA-approved drugs to determine if they could be repurposed or improved to help patients with a rare, debilitating disease of the nervous system.

16 Feb 2023

Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery

Inventia Life Science, a world leader in advanced cell models for biomedical research and drug discovery, today announced a collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) using Inventia’s RASTRUM™ 3D cell culture platform.

From Inventia Life Science 16 Feb 2023

Scientists discover a protein in the lung that blocks SARS-CoV-2 infection

University of Sydney scientists have discovered a protein in the lung that blocks SARS-CoV-2 infection and forms a natural protective barrier in the human body.

9 Feb 2023

Fluidic Analytics showcases protein analysis expertise across Europe

Fluidic Analytics Ltd, a pioneer in protein analysis and the company behind in-solution diffusional sizing, will attend a number of events this Autumn to showcase its revolutionary technology for studying protein interactions.

From Fluidic Analytics 8 Feb 2023

Professor Sara Linse presents new data on protein interactions in Alzheimer’s disease using the Fluidity One-W at FEBS 2019

Fluidic Analytics’ diffusional sizing technology has been influential in a recent study that investigates protein binding and self-assembly in Alzheimer’s disease.

From Fluidic Analytics 8 Feb 2023

Researchers develop a new method to design peptide antibiotics

Hokkaido University researchers have developed a novel method to design and develop peptide antibiotics in large numbers, which will prove critical to controlling antibiotic resistance.

7 Feb 2023

Mucoactive drugs block SARS-CoV-2 infection

Researchers evaluate the effects of mucociliary active molecules on SARS-CoV-2 infection in vitro.

7 Feb 2023

USC researchers identify two promising avenues for developing new ALS treatments

Each year in the U.S., 5,000 patients receive a diagnosis of ALS, an incurable neurodegenerative disease that will likely kill them within two to five years.

7 Feb 2023

Targeting a single enzyme can kill prostate cancer cells

For the first time, researchers have discovered that prostate cancer can be killed by targeting a single enzyme, called PI5P4Kα.

3 Feb 2023

Oncodesign Services looks to the future

As Oncodesign evolves into Oncodesign Services and begins its journey as an independent business, CEO Fabrice Viviani explains his hopes and plans for the company’s future.

From Oncodesign Services 3 Feb 2023

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services, a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, representing 61.58% of its share capital, from its main shareholders, including Mr. Philippe Genne, Founder of Oncodesign Services, as well as certain key shareholders and several managers and minority shareholders, following the entry into exclusive negotiations on June 30, 2022.

From Oncodesign Services 3 Feb 2023

Drug Discovery News and Research

Further Reading

When cancer research turns to the immune system – the critical role of peptides and immunopeptidomics

Ketamine appears to hold promise in treating cocaine-use disorders

Utilizing CRISPR to discover new therapy options for COPD

Scientists discover how a "poisoned" form of protein could spur cancer formation

Beckman Coulter Life Sciences presenting at SLAS2023

Pharma companies could provide new, affordable drugs by refocusing their spending, experts say

Repurposing or improving drugs for spinocerebellar ataxia type 5

Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery

Scientists discover a protein in the lung that blocks SARS-CoV-2 infection

Fluidic Analytics showcases protein analysis expertise across Europe

Professor Sara Linse presents new data on protein interactions in Alzheimer’s disease using the Fluidity One-W at FEBS 2019

Researchers develop a new method to design peptide antibiotics

Mucoactive drugs block SARS-CoV-2 infection

USC researchers identify two promising avenues for developing new ALS treatments

Targeting a single enzyme can kill prostate cancer cells

Oncodesign Services looks to the future

ERES IV acquires a majority stake in Oncodesign Services

CuSTOM; Creating a healthier society by accelerating the translation of organoid technology

A high-throughput screening assay for small molecule inhibitors of the antigen aminopeptidase ERAP1

Aston University scientists team up with Isterian Biotech to develop novel drugs to treat fibrotic diseases

Binding kinetics in drug discovery eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo